Recent developments in the field of 123I-radiopharmaceuticals.
Due to its advantageous nuclear physical properties iodine-123 is an excellent label for radiopharmaceuticals very well suited for measurements by gamma-cameras and single-photon emission tomography. The development of 123I-radiopharmaceuticals should be based on a clear biochemical concept, reliable labelling procedures and careful pharmacokinetic studies in order to evaluate the physiological behaviour of the radioiodinated compounds being analogues of metabolic substrates. The development of 123I-labelled fatty acids and biogenic amines clearly proved the successful use of 123I for labelling compounds applied in medical diagnosis.
D000662:Amphetamines; D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging*; D002539:Cerebral Arterial Diseases / Q000000981:diagnostic imaging; D003327:Coronary Disease / Q000000981:diagnostic imaging; D005227:Fatty Acids; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D020367:Iofetamine; D007553:Isotope Labeling / Q000379:methods; D051379:Mice; D008875:Middle Aged; D051381:Rats; D014055:Tomography, Emission-Computed
D000662:Amphetamines; D005227:Fatty Acids; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; C027252:17-iodoheptadecanoic acid; C025391:omega-(4-iodophenyl)pentadecanoic acid; D020367:Iofetamine